{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:42:41Z","timestamp":1792510961974,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Emerg Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is increasingly used for obesity treatment, including in individuals without diabetes. Starvation ketoacidosis is a rare but serious complication associated with reduced caloric intake and enhanced ketogenesis. Reports of tirzepatide-associated starvation ketoacidosis in non-diabetic patients remain limited, and none have been reported in East Asian populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 21-year-old Japanese woman with obesity initiated weekly subcutaneous tirzepatide (2.5\u00a0mg\/week) for weight loss while practicing carbohydrate restriction. After the fifth injection, she developed persistent nausea and vomiting, leading to markedly reduced oral intake. She presented to the emergency department with hypoglycemia (68\u00a0mg\/dL) and severe high\u2013anion gap metabolic acidosis (pH 7.22, bicarbonate 10 mmol\/L, anion gap 22.6 mmol\/L). Urinalysis revealed ketonuria, and serum ketone levels were markedly elevated. She had lost 21\u00a0kg one month after the initiation of tirzepatide. No infection, toxin exposure, or alternative metabolic disorder was identified. Starvation ketoacidosis was diagnosed. Treatment with intravenous glucose-containing fluids resulted in rapid resolution of metabolic acidosis within 12\u00a0h without insulin therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case demonstrates that tirzepatide can precipitate starvation ketoacidosis in non-diabetic individuals, particularly when gastrointestinal adverse effects or dietary restriction lead to caloric deprivation. As the first reported case in an East Asian patient, it highlights the need for emergency physicians to consider starvation ketoacidosis in patients using tirzepatide for weight loss who present with vomiting, poor intake, or rapid weight loss. Early recognition and appropriate metabolic assessment are essential, and in patients with preserved endogenous insulin secretion, prompt glucose administration may allow rapid recovery without need for insulin therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12245-026-01170-9","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:23:04Z","timestamp":1773660184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Starvation ketoacidosis associated with tirzepatide use for weight loss in a non-diabetic East Asian woman: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Yuki","family":"Minoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuhei","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Kishitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotada","family":"Kittaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Sawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"5","key":"1170_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/ANNALS-24-02870","volume":"178","author":"JW Ostrominski","year":"2025","unstructured":"Ostrominski JW, Ortega-Montiel J, Tesfaye H, Alix C, DiCesare E, Cromer SJ, et al. Trends in utilization of glucose- and weight-lowering medications after tirzepatide approval in the United States: a population-based cohort study. Ann Intern Med. 2025;178(5):620\u201333. https:\/\/doi.org\/10.7326\/ANNALS-24-02870.","journal-title":"Ann Intern Med"},{"key":"1170_CR2","unstructured":"Tanabe Mitsubishi Pharma Corporation. Announcement of NHI price listing and launch date of Zepbound\u00ae (long-acting GIP\/GLP-1 receptor agonist). 2025. https:\/\/www.tanabe-pharma.com\/ja\/news\/MTPC250319.html"},{"issue":"6","key":"1170_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"key":"1170_CR4","unstructured":"Eli Lilly and Company. MOUNJARO (tirzepatide) prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215866s010s015s022lbl.pdf. Accessed 12 Dec 2025."},{"issue":"1","key":"1170_CR5","doi-asserted-by":"publisher","first-page":"e2457232","DOI":"10.1001\/jamanetworkopen.2024.57232","volume":"8","author":"JT Berning","year":"2025","unstructured":"Berning JT, Adhikari R, Schroer AE, Jelwan YA, Razavi AC, Blaha MJ, et al. Longitudinal analysis of obesity drug use and public awareness. JAMA Netw Open. 2025;8(1):e2457232. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57232.","journal-title":"JAMA Netw Open"},{"key":"1170_CR6","unstructured":"American Diabetes Association. Understanding diabetic ketoacidosis (DKA) in clinical practice. Standards of Care in Diabetes\u20142024. American Diabetes Association. 2024. https:\/\/professional.diabetes.org\/sites\/dpro\/files\/2024-12\/understanding-dka.pdf. Accessed 12 Feb 2026."},{"issue":"6","key":"1170_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/s41366-025-01749-x","volume":"49","author":"N Sood","year":"2025","unstructured":"Sood N, Buddhavarapu V, Garg R. GLP-1 receptor agonists causing euglycemic ketoacidosis in patients without diabetes: a brief review. Int J Obes (Lond). 2025;49(6):977\u20139. https:\/\/doi.org\/10.1038\/s41366-025-01749-x.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"1170_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11606-024-09073-2","volume":"40","author":"R Garg","year":"2025","unstructured":"Garg R, Sood N, Bansal O, Hoskote A. Euglycemic ketoacidosis associated with SGLT-2 inhibitors in non-diabetic patients: a narrative review. J Gen Intern Med. 2025;40(2):437\u201342. https:\/\/doi.org\/10.1007\/s11606-024-09073-2.","journal-title":"J Gen Intern Med"},{"key":"1170_CR9","unstructured":"Eli Lilly and Company. MOUNJARO (tirzepatide) prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf. Accessed 12 Dec 2025."},{"key":"1170_CR10","doi-asserted-by":"publisher","first-page":"1463657","DOI":"10.3389\/fphar.2024.1463657","volume":"15","author":"Y Ou","year":"2024","unstructured":"Ou Y, Cui Z, Lou S, Zhu C, Chen J, Zhou L, et al. Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups. Front Pharmacol. 2024;15:1463657. https:\/\/doi.org\/10.3389\/fphar.2024.1463657.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1170_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5455\/medarh.2022.76.221-223","volume":"76","author":"M Alghamdi","year":"2022","unstructured":"Alghamdi M, Almulhim M, Alkhadra F, Alahmadi S, Alzahid A, Al-Mulhim A. A Liraglutide Injection Superimposing a Starvation Acidosis: a Case Report. Med Arch. 2022;76(3):221\u20133. https:\/\/doi.org\/10.5455\/medarh.2022.76.221-223.","journal-title":"Med Arch"},{"issue":"12","key":"1170_CR12","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/15563650.2023.2277337","volume":"61","author":"J Mercer","year":"2023","unstructured":"Mercer J, Lipscomb J, Lipscomba J, Gao HT, King K. Tirzepatide-associated starvation ketoacidosis. Clin Toxicol (Phila). 2023;61(12):1064\u20135. https:\/\/doi.org\/10.1080\/15563650.2023.2277337.","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"1170_CR13","doi-asserted-by":"publisher","first-page":"004357","DOI":"10.12890\/2024_004357","volume":"11","author":"PMR Iqbal","year":"2024","unstructured":"Iqbal PMR, Maadarani OS, Bitar ZI. Tirzepatide-induced ketoacidosis in non-diabetic patients. Eur J Case Rep Intern Med. 2024;11(4):004357. https:\/\/doi.org\/10.12890\/2024_004357.","journal-title":"Eur J Case Rep Intern Med"},{"issue":"9","key":"1170_CR14","doi-asserted-by":"publisher","first-page":"luae156","DOI":"10.1210\/jcemcr\/luae156","volume":"2","author":"N Sood","year":"2024","unstructured":"Sood N, Bansal O, Garg R, Hoskote A. Euglycemic ketoacidosis from semaglutide in a patient without diabetes. JCEM Case Rep. 2024;2(9):luae156. https:\/\/doi.org\/10.1210\/jcemcr\/luae156.","journal-title":"JCEM Case Rep"},{"key":"1170_CR15","doi-asserted-by":"publisher","first-page":"e946133","DOI":"10.12659\/AJCR.946133","volume":"25","author":"Z Bitar","year":"2024","unstructured":"Bitar Z, Abdelraouf HM, Maig RA, Maadarani O, Bitar ZZ, Dashti H. Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: is starvation the culprit? Am J Case Rep. 2024;25:e946133. https:\/\/doi.org\/10.12659\/AJCR.946133.","journal-title":"Am J Case Rep"},{"issue":"4","key":"1170_CR16","doi-asserted-by":"publisher","first-page":"e83187","DOI":"10.7759\/cureus.83187","volume":"17","author":"R Singh","year":"2025","unstructured":"Singh R. Euglycemic ketoacidosis in a non-diabetic patient after tirzepatide use: a cautionary tale. Cureus. 2025;17(4):e83187. https:\/\/doi.org\/10.7759\/cureus.83187.","journal-title":"Cureus"},{"issue":"4","key":"1170_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.maturitas.2009.12.012","volume":"65","author":"SN Wulan","year":"2010","unstructured":"Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. Maturitas. 2010;65(4):315\u201319. https:\/\/doi.org\/10.1016\/j.maturitas.2009.12.012.","journal-title":"Maturitas"},{"issue":"2","key":"1170_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","volume":"106","author":"MK Thomas","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388\u201396. https:\/\/doi.org\/10.1210\/clinem\/dgaa863.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["International Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12245-026-01170-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12245-026-01170-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12245-026-01170-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:56:42Z","timestamp":1776902202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12245-026-01170-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1186\/s12245-026-01170-9","relation":{},"ISSN":["1865-1380"],"issn-type":[{"value":"1865-1380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}